Projectes Internacionals

PROJECTES INTERNACIONALS – INTERNATIONAL PROJECTES


Projectes internacionals amb la amb la participació i/o direcció de membres del Grup (en odre, de més nou a més antic)
International projects with the participation and/or management of members of the Group (in oder, from newest to oldest)
Act. 12/2024




Funding body: National Institutes of Health (NIH) - National Institute of Ageing, USA
Project title: EThe Microbiome-Gut-Brain Axis and Personalized Mediterranean Diet Interventions for Alzheimer's Dementia Prevention.
Referece: 1RF1AG083764-01A1
Duration: 15/05/2024 - 30/04/2027.
Principal Investigators: Dr. Dong Wang (Brigham & Womens Hospital, Boston)
Co-principal investigators: D Corella; M Ruiz-Canela, J, Salas-Salvadó, FJ Tinahones.
 

Funding body: Madras Diabetes Research Foundation (MDRF)
Project title: Effect of peanuts on cardiometabolic risk and general wellness among overweight and obese Asian Indians
Duration: April 2024 to ….
Principal Investigators: Dr. Shilpa N Bhupathiraju, Channing Division of Network Medicine, Harvard Medical School and Brigham and Women's Hospital, and  Dr. Anjana Ranjit Mohan, Madras Diabetes Research Foundation, Chennai, India.
Collaborators: Dr. Vishwanath Mohan (MDRF), Ms. Sudha Vasudevan (MDRF), Dr. Shobhana Shanmugham (MDRF), Dr. Walter Willett (Harvard), Dr. Jordi Salas Salvadó (Rovira i Virgili Univesity, Spain)
 

​
Funding body: International Nut Council (INC)
Project title: Nut Consumption and Risk of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis (NUTPOOL)
Duration: 01-02-2024 to 30-01-2027 - 3 years
Principal Investigator: Dr. Marta Guasch-Ferré, University of Copenhagen, Department of Public Health (UCPH), Denmark
Co-Principal Investigator: Dr. Jordi Salas-Salvadó, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Spain
Other Group Investigators: Nancy Babio, Sangeetha Shyam, Francisco García-Gavilán, researcher's Group colaborators.
http://www.nutpool.eu
 

​
Funding body: Almond Board of California - (USA)
Project title: Characterization and validation of a plasma metabolomic signature of almonds in randomized controlled trials of the portfolio diet.
Principal Applicant: Sievenpiper JL.
Position in the project: Glenn AJ, Kendall CWC, Hu F, Salas-Salvado J, Jenkins DJA (Co-aplicants).
Duration: 2023 to 2025
 

​
Funding body: Ministry of Higher Education - (Malaysia)
Project title: Elucidating the Gut Microbiome and Health Risks Behaviours as Mediators to Food Security and Non-Communicable Chronic Diseases among Low-Income Urban Dwellers
Aplication ID: 481810-495949
Selected Grant Scheme: FRGS 2023-1
Principal Investigators: Prof. Barakatun Nisak Binti Mohd Yusof – Universiti Putra Malaysia (UPM)
Position in the project: Salas-Salvadó J, Shyam S, García-Gavilán JF, researcher's Group colaborators.
Duration: 02/10/2023 to 30-10-2025

Executive Summary of Research Proposal
Malaysia's food security remains challenging. Lack of food access and utilization due to food insecurity is often overlooked in clinical practices, which could explain the rising pandemic of non-communicable diseases (NCDs). This catastrophe impacts low-income urban dwellers the most, who rely on food purchases that are cheap, energy-dense and low in nutrients. While there are many studies on food security and health, the extent to which it is linked to gut microbiota has not been discovered. We know that poor diet influences gut microbiome and health risks, but how these factors mediate food security status and accelerate pathologic pathways to NCDs is unknown. Thus, elucidating the mechanisms that mediate the relationship between food security status and NCDs would address the gaps. This study aims to investigate the gut microbiome and health risk behaviours as mediators of the link between food security status and NCDs among low-income urban dwellers. This study employs a cross-sectional study involving 550 adults identified as low-income, staying in Selangor-urban areas from the eKasih database. A structured questionnaire will be administered to obtain information on the built environment and socioeconomic factors, food security, health behaviour risks, and dietary intake. The medical history and health access will be assessed to identify NCDs status, and blood will be withdrawn to confirm disease control. Food intake will be obtained to identify a specific dietary pattern associated with food security. A sub-sample based on food insecurity status (n=100) will be purposively sampled and undergo a further assessment of gut microbiota and health risks behaviours (lifestyle risks, pathophysiological responses). Data can be mapped to establish a cost-effective, healthy dietary plan. This exciting work would discover new interplay in food security for NCD control, complementing the agricultural and food system components to transform Malaysia into a more food-secure nation.

​
Funding body: European Commission
Call: HORIZON-CL6-2023-FARM2FORK-01
Proposal Number 101137127.
Project title: Tackling micronutrient malnutrition & hidden hunger to improve health in the EU.
Acronym: Zero_HiddenHunger_EU
Type of Model Grant Agreement: HORIZON Action Grant Budget-Based
Funded entitty: University College Cork - National University of Ireland, Cork
Project coordinator: Kevin Cashman
Duration: 01/01/2024 - 31/12/27 (48 months).
Integrated Group (Partner): Centro de Investigacion Biomedica en Red MP (Ciber)
IP integrated group (CIBER): Luis Moreno Aznar
Position in the project: Salas-Salvadó J & Babio N  - Team CIBER Research Members
 

​​
Funding body: International Medical Universtiy – Kuala Lumpur (Malaysia)
Project title: Nutrient quality of plant-based meat products and their corresponding products of animal available in hypermarkets around Bukit Jalil: a cross sectional study.
File: BNT I-2023 (01)
Principal Investigators: Dr. Snigdha Misra
Position in the project: Salas-Salvadó J, Babio N & Shyam S, researcher’s Group colaborators.
Duration: 31/07/2023 to 29-12-2023
 

​
Funding body: International Nut Council (INC)
Convocatory 2022 Call for Research Projects
Project title: Effect of Nut Consumption on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [Efecto del consumo de frutos secos sobre los lípidos en sangre: una revisión sistemática y un metanálisis de ensayos controlados aleatorios]
Duration: 05/10/2022 - 05/10/2023
Principal Investigator(s) Salas-Salvadó J, Babio N, Nishi S.
Other Group Investigators: Paz Graniel I, García-Gavilán J, Ni J, Valle C, Khoury N, researcher's Group colaborators.
 

​​
Funding body: Canadian Institutes of Health Research
Project title: An innovative technology-based approach to translating clinical practice guidelines of nutrition therapy in primary care: The Cost, Health, and Effectiveness Assessment of the Portfolio diet in Primary care (CHEAPP) program
Principal Investigators: John Lamport Sievenpiper; David John Anthony Jenkins; Lawrence Alan Leiter
Position in the project: Salas-Salvadó J, associated investigator
Duration: 02/02/2022 to 02/02/2027

Description

Cardiovascular disease results in 25% of deaths in Canada, costing over $21 billion annually. Nutrition and lifestyle remain the cornerstone of therapy for cardiovascular disease, but implementation is limited. Dietitian services in Canada are not covered by provincial health plans and most physicians cite a lack of education, tools and time to counsel on nutrition. Innovative self-management tools, such as web-based apps, provide a complementary and affordable approach for delivery of dietary advice, especially with the transition to virtual care during the COVID-19 pandemic. The Portfolio Diet, a plant-based dietary pattern of cholesterol-lowering foods which has demonstrated "drug-like" reductions in cholesterol and other cardiovascular risk factors, is uniquely positioned to test this innovative approach. We have developed the PortfolioDiet.app, as a direct translation of the Canadian Cardiovascular Society (CCS), Diabetes Canada, and Obesity Canada Clinical Practice Guidelines for the nutritional management of cholesterol. In collaboration with a unique and diverse group of experts in nutrition, cardiovascular disease, healthcare app development and evaluation, and health economics, and patient and physician advisory committees, we propose a 1-year trial to assess the clinical impact of the PortfolioDiet.app as add-on therapy to the standard of care (usual care) in individuals with high cholesterol in primary care. This intervention will demonstrate how clinical practice guidelines can be effectively translated using the PortfolioDiet.app to improve the cholesterol management and overall cardiovascular health while improving the patient and physician experience and reducing health care costs. The results will have a major influence on the translation of dietary guidelines, demonstrating the extent to which the Portfolio diet approach is an effective option for improving cardiovascular health and delivering a ready-to-use clinical tool in primary care.
 

Funding body: Diabetes Canada
Project title: The Role of the Portfolio Diet in the Prevention of Heart Disease and Diabetes: Insights from Clinical and Population Studies using Markers of Metabolism and Genetics
Aplication ID: OG-3-21-5582-JS
Principal Applicant: Sievenpiper JL.
Position in the project:  Salas-Salvado J (Co-aplicants).
Duration: 2021 to 2024

Summary:
People living with diabetes take many medications to help manage their blood sugar and decrease their risk of heart disease, and some medications have unwanted side effects. Healthy diets remain the cornerstone of heart disease and diabetes prevention and management. These diets typically have no unwanted side effects and can improve many important risk factors for diabetes and heart disease at the same time. However, the research to support specific diet strategies for diabetes and heart disease is limited. Innovative nutrition research is needed that will strengthen the evidence for clinical and public health policy decision-making. Metabolomics is an emerging field in nutrition and chronic disease epidemiology. This approach uses overall metabolism products to develop an objective metabolic signature for a dietary pattern, which is not prone to the same measurement and reporting errors of traditional self-report diet tools. This approach can also be used to produce a genetic signature that will allow for the assessment of causal relationships, thereby providing important evidence for the role of diet in the prevention of diabetes and heart disease.
We now plan to expand our work with the Portfolio Diet, a plant-based dietary portfolio of cholesterol-lowering foods (nuts, plant protein, sticky fibre, plant sterols, and healthy oils), to include this new transformative approach. We will: (1)Determine a metabolic signature of the Portfolio Diet from a trial and, (2)Apply and compare this metabolic signature to three large U.S. cohorts and assess the relation of the Portfolio Diet, its metabolic signature, and inferred genetic signature with heart disease and type 2 diabetes.
The majority of individuals with type 2 diabetes will die prematurely of heart disease in Canada and worldwide, and so research like ours aims to identify dietary patterns to prevent and manage these chronic diseases that could impact millions of people.

​
Funding Agency: US National Health Institute (USA)
Institute: National Institute of Diabetes and Digestive and Kidney Diseases
Program: NIH Research Project Grant
FOA: PA-19-056
Project title: Lifestyle Interventions, metabolites, microbiome, and diabetes risk (NIH)
Study Section: Special Emphasis Panel (ZRG1)
Project Number: R01DK127601
Agreement: 11327-5116522
Project Leader: Frank Hu (Harvard University, USA)
Organization: HARVARD SCHOOL OF PUBLIC HEALTH, BOSTON, USA
Principal investigators: HU, F (IP Harvard T. H. Chan School of Public Health); SALAS SALVADÓ, J (IP URV); RUIZ-CANELA, M (IP UNAV)
Project Start Date: 15-March-2021
Project End Date: 31-January-2025

https://reporter.nih.gov/search/ROel7ZoJBEeKxjAoNRNigw/project-details/10140490#details
https://grantome.com/grant/NIH/R01-DK127601-01 (first year)

Abstract
This application is an ancillary study of the PREDIMED-Plus trial to examine the effects of a diet and lifestyle intervention on incidence of T2D as a secondary endpoint among 4,770 participants who were non-diabetics at baseline. PREDIMED-Plus is an ongoing primary cardiovascular prevention trial (www.predimedplus.com), which has recruited 6,874 women and men (aged 55 to 75 years) between October 2013 and December 2016. Participants were randomly allocated to 2 groups: an energy-reduced Mediterranean diet (MedDiet) group, with physical activity and behavioral support for weight loss; or a control group receiving low-intensity advice on the MedDiet. The intervention will last 6 years. We will examine four Specific Aims. First, we will evaluate whether an intensive lifestyle intervention consisting of an energy-reduced MedDiet, increased physical activity, and weight loss, reduces the incidence of T2D comparied with the control group (intervention group n=2,384; control group n=2,451). Second, we will evaluate the effect of the lifestyle intervention on total fat mass and visceral adipose tissue (VAT) measured by Dual-energy X-ray Absorptiometry (DXA) after 1, 3, and 6-year intervention in a subsample (n=1,569). Third, we will examine whether the lifestyle intervention modifies the association of the metabolite risk score (MRS) with the incidence of T2D in a nested case-control study (n=620 incident T2D cases and 620 matched controls). These analyses will be replicated in the multi-ethnic US Diabetes Prevention Program (DPP, 775 cases and 1,386 non-cases from the placebo/lifestyle groups). Fourth, we will examine whether the intervention induces beneficial changes in stool metabolites from baseline to year 1, in a subsample of 250 participants in the intervention group and 250 in the control group. We will also examine whether changes in stool metabolites are associated with changes in gut microbiome induced by the intervention. The preliminary results among the PREDIMED-Plus participants showed that the intervention significantly reduced body weight and HbA1c, which was sustained over three years. This study builds upon a large RCT and will be the first and largest of its kind to prospectively assess the effects of an intensive lifestyle intervention on plasma and stool metabolites and the risk of T2D, using the state-of-the-art LC-MS platform and cutting-edge bioinformatics and statistical methods. Objective measures will be used to assess functional fitness (a 30-second chair sit- and-stand (CSS) test), physical activity (accelerometers), body composition (DXA), and extra-virgin olive oil consumption (urinary tyrosol and hydroxytyrosol levels). This application has the potential to advance our understanding of T2D pathophysiology and inform precision nutrition and T2D prevention. It has important implications for the US population because it may provide further evidence to strengthen current recommendations on the MedDiet as a part of a healthy lifestyle for chronic disease prevention.
 

​

​
Funding body: The National Institutes of Health (NIH), USA
Program: NIH Research Project Grant
Project title: Mediterranean diet, Metabolites, and Cardiovascular Disease (NIH)
Reference: 2R01HL118264-09
Principal Investigators: Rosa M Lamuela-Raventos; Frank Hu; Miguel A Martínez; Fredrick J. Stare
Position in the project: Salas-Salvadó J, associated investigator
Duration: 01-March-2022 to 28-February-2023

ABSTRACT
Metabolomics technique holds promise for better understanding the role of diet in cardiovascular disease (CVD) epidemiology and prevention. In particular, a multi-fluid multi-metabolite approach combining urinary and plasma metabolomics will likely enhance the accuracy and precision of nutritional biomarkers, with strong potential to develop novel tools for dietary assessment in precision nutrition research. This competing renewal is aimed to examine the effects of the randomized Mediterranean diet (MedDiet) interventions on urinary metabolite levels and to assess dietary biomarkers' predictive ability for future CVD risk in the landmark PREDIMED trial. We will assess urinary metabolomics in relation to CVD through a case-cohort design, including a representative subcohort randomly sampled from all PREDIMED participants (10%, n=779), and incident CVD cases (including myocardial infarction (MI), stroke, heart failure, and cardiovascular deaths) through December 2017 (n=529). The proposed Specific Aims are: (1) To identify specific urinary metabolites and multi-metabolite signatures of the MedDiet pattern and its main food components; (2) To examine the effects of the randomized dietary interventions on changes in the urinary multi-metabolite signatures of the MedDiet pattern and its major food components from baseline to year 1 (post intervention); (3) To investigate whether baseline and 1-year changes in urinary multi-metabolite signatures of the MedDiet pattern and of individual foods are associated with subsequent risk of CVD; and (4) To develop a multi-fluid (urine and plasma) multi-metabolite signature that robustly predicts risk of CVD and assess whether 1-year changes in the signature mediate the effects of the dietary interventions on the composite CVD outcome. As a sub-aim, we will compare the predictive roles of plasma and urinary metabolites of the MedDiet pattern on CVD risk. This ongoing grant started in 2013 and was renewed in 2017. To date, 36 papers have been published or submitted (including 20 papers in the current grant cycle). The PREDIMED metabolomics data have been used as a resource for replicating metabolomics analyses of CVD outcomes in several US cohorts. This competing renewal application will extend our long-standing research on MedDiet and CVD to multi-fluid multi- metabolite profiling in a large randomized intervention trial. This project leverages numerous strengths of the PREDIMED trial, a multi-disciplinary and highly productive team, cutting-edge metabolomics technologies, and high-dimensional data analytics. The identified dietary biomarkers will enhance the quality and rigor of nutrition research and strengthen the evidence base for developing dietary recommendations and nutrition policies. The proposed work will facilitate the precision nutrition research agenda outlined in the 2020-2030 Strategic Plan for NIH Nutrition Research.

https://reporter.nih.gov/search/3yl_BW8pXEqrMfb_hzsmFQ/project-details/10385953#details

​​ ​​
Funding Agency: European Commission
Project title: Prevention and Remediation of Insulin Multimorbidity in Europe (PRIME).
Announcement: H2020-SC1-BHC-2018-2020.
Proposal number: SEP-210574986.
Grant agreement ID: 847879
Project coordinator: Barbara Franke
Coordinated by: STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM, The Netherlands
Members of the group participants as researchers: Salas-Salvadó J, Co-Investigator.
Duration: 01/01/2020 to 31/12/2024.
https://prime-study.eu/
https://cordis.europa.eu/project/id/847879/results

What is PRIME?

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 - 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer's disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or 'multimorbidity') with somatic conditions.
Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.
 

​​ ​​
Funding body: European Commission
Project title: Science and Technology in childhood Obesity Policy (STOP)
Call: Horizon 2020 European Union Funding for Research & Innovation
Funded under:  Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy
Topic: SFS-39-2017: Sustainable Food Security - Resilient and resource efficient value),
Reference: H2020 ref.774548
Coodinator of the study: Franco Sassi
Coordinated by: Coordinated by IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE, UK
Co-Investigador principal: Josep Antoni Tur Marí
Agreement reference: 774548-2
Members of the group participants as researchers: Salas-Salvadó J, Babio N.
Duration: 01/06/2018 to 30/11/2022
http://www.stopchildobesity.eu/
https://cordis.europa.eu/project/id/774548

What is STOP?
Over a four-year period (2018-22), the STOP project will generate scientifically sound, novel and policy-relevant evidence on the factors that have contributed to the spread of childhood obesity in European countries and on the effects of alternative technological and organisational solutions and policy options available to address the problem.
The STOP project will translate the evidence gathered and generated into:
Indicators and measurements: A comprehensive set of indicators and a measurement framework for the epidemiological surveillance of relevant dimensions of childhood obesity, its determinants and actions to address it in all European countries.
Policy briefs and toolkits: Policy briefs and toolkits providing practical guidance and tools for the design and the implementation of key policies.
Multi-stakeholder framework: A viable multi-stakeholder framework based on effective communication and negotiation approaches, a sound use of the existing evidence base, and appropriate mechanisms for setting targets, monitoring progress and evaluating actions.
In line with the WHO Commission on Ending Childhood Obesity (ECHO) and with the EU Joint Action on Nutrition and Physical Activity (JANPA), STOP will adopt a life course and intergenerational perspective, assessing the role of determinants of childhood obesity before birth and in the earliest years of life, as well as the role of parenting and parental lifestyles, and the long-term links between childhood obesity, adult obesity and disease throughout the life course. STOP will emphasise the environmental dimension of childhood obesity, recognising the role of different environments surrounding children as major contributors to obesity, and the diverse characterisations of obesity, with a special emphasis on those associated with the most detrimental outcomes in vulnerable and socially disadvantaged children.
The project brings together major health and food sector actors, including scientists, health professionals, government policy makers, national public health agencies, international organisations, civil society and business organisations. STOP will establish new ways for policy-relevant evidence to be generated, made available and used in the design and implementation of effective and sustainable solutions for childhood obesity at the EU, national and local levels.
 

​​ ​​
Funding Agency: European Commission
Project title: Effects of Nutrition and Lifestyle on Impulsive, Compulsive, and Externalizing behaviors (Eat2beNICE). Grant: 728018
Coordinating centre: Stichting Radboud Universiteit (Netherlands)
Coordinating Researcher: Alejandro Arias Vásquez
Principal Investigator: Ramos Quiroga, José Antonio
Principal Investigator WP5: Fernández Aranda, Fernando
Members of the group participants as researchers: Salas-Salvadó J, Co-Investigator WP5
Reference: EAT2BENICE_H2020_SFS2016
Duration: 01-Sep-2017 to 28-Feb-2023
http://cordis.europa.eu/project/rcn/210507_es.html
https://newbrainnutrition.com/

We are an EU-funded medical consortium that studies the connections between gut microbiota, diet, and exercise to formulate nutrition and lifestyle recommendations for brain health. Early research has shown evidence of a sizeable impact of nutrition on behaviours such as impulsivity and compulsivity. We are therefore interested in studying how dietary components (including sugar, fat and protein content, vitamin and mineral supplements, food additives and probiotics) and lifestyle factors (including exercise) influence people's overall health, brain function and behaviour. Specifically, we aim to identify nutritional drivers and lifestyle variations that could prevent harmful effects on impulsivity and compulsivity across the lifespan. This will enable us to better understand the paths leading to impulsivity and compulsivity in the brain via the gut (microbiota and their metabolic effects). We aim to promote societal changes that will counteract maladaptive impulsivity and compulsivity by bringing evidence-based information about health-related behaviours to families, clinicians, policymakers and the general public.
 

PROJECTES FINALITZATS – FINALIZED PROJECTS

​​
Funding Agency: US National Health Institute (USA)
Institute: National Heart, Lung, and Blood Institute (NHLBI)
Program: NIH Research Project Grant
Project title: Mediterranean diet, Metabolites, and cardiovascular Disease (NIH)
Project Number: 2R01HL118264-05
Agreement: 111246-5103557
Project Leader: Frank Hu (Harvard University, USA)
Organization: HARVARD SCHOOL OF PUBLIC HEALTH, BOSTON, USA
Study Section: Cancer, Heart, and Sleep Epidemiology B Study Section (CHSB)
Application#: 9388404
Principal Investigators: Frank Hu, Salas-Salvadó J, Fitó M, Martínez MA, Corella D, Estruch R.
Project Start Date: 20-August-2017
Project End Date: 30-June-2022

Abstract
Heart failure (HF), atrial fibrillation (AF), and peripheral artery disease (PAD) have emerged as important cardiovascular diseases (CVDs) contributing to the increasing burden of chronic diseases and escalating health care costs in the United States and globally. Recent advances in metabolomics have allowed investigators to assay hundreds of metabolites from a small volume of blood, providing a comprehensive picture of an individual's metabolic status that may underlie the effects of diet on disease risk. However, few studies have assessed the association between metabolite profiles and risk of HF, AF, and PAD. In this competing rewewal application, we propose a nested case-control design to conduct targeted and untargeted metabolomics analyses of incident cases of HF (n=332), AF (n=594), and PAD (n=196) and matched controls in a cohort of 7,447 participants during the active intervention and extended follow-up periods (2003-2018) in the PREDIMED trial. Our specific aims are: 1). To examine the associations between approximately 400 known metabolites at baseline and risk of HF, AF, and PAD, using a nested case-control design. 2). To conduct pathway analysis and agnostic network modeling that integrate non-targeted metabolites with known metabolites to identify novel metabolomic signatures of risk of HF, AF, and PAD. 3). To assess whether the randomized dietary interventions modify the effect of baseline metabolite profiles on HF, AF, and PAD risk. In addition, we will explore both unique and common metabolites and metabolic pathways associated with incident HF, AF, and PAD and will replicate novel metabolites identified in the PREDIMED cohort in the Atherosclerosis Risk in Communities (ARIC) study, an independent multi-ethnic cohort in the US. This competing renewal application represents an extension of our long-standing research on the Mediterranean diet and CVD to new clinical endpoints in the context of the landmark PREDIMED trial. This research has important implications for the US population because the current Dietary Guidelines for Americans recommend the Mediterranean diet as one of healthy dietary patterns for CVD prevention. The current cycle of the grant has been highly productive with 11 papers published or submitted, contributing to new knowledge about mechanisms underlying diet and CVD and new statistical methods for analyzing nutritional metabolomics data. This competing renewal, built on the numerous strengths of the PREDIMED trial and a multi-disciplinary and cohesive team, has the potential to advance our understanding of CVD pathophysiology and produce knowledge that can directly inform specific dietary interventions to prevent overall CVD and its subtypes.

https://reporter.nih.gov/search/ROel7ZoJBEeKxjAoNRNigw/project-details/10140490#details
https://grantome.com/grant/NIH/R01-HL118264-08

​​
Funding body: European Commission
Project title: Long-term effects of an energy-restricted Mediterranean diet on mortality and cardiovascular disease: the PREDIMED PLUS Study.
Grant agreement ID: 340918
Funded under: FP7-IDEAS-ERC
Programme: FP7-IDEAS-ERC - Specific Programme: 'Ideas' implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013). Thematic: ERC-AG-LS7 - ERC Advanced Grant - Diagnostic tools, therapies and public health
Duration: 01/05/2014 -30/04/2019
Coordinator: Miguel Ángel Marínez
Members of the group participants as researchers: Salas-Salvadó J, Principal Investigator CIBERobn (European PREDIMED Third Party Project)
https://cordis.europa.eu/project/rcn/188509/factsheet/es

The impact of weight loss on cardiovascular disease risk within the frame of the Mediterranean dietary pattern has not yet been tested using a sufficiently large randomized trial (Malik, Hu, 2007). We propose to run a parallel group, multi-center, randomized, primary prevention trial (PREDIMED PLUS) on men aged 55-75 years and women 65-75 years, with a body mass index ≥27 to <40 kg/m2 and meeting at least 3 criteria for the metabolic syndrome. The objective of the present research is to address the cardiovascular effect of an intensive weight-loss lifestyle intervention based on an energy-restricted traditional Mediterranean diet in comparison with a less intensive program using Mediterranean diet, but with no energy restriction, behavioural intervention or physical activity programme. The end-point is a composite of major hard clinical cardiovascular events. We hypothesize that an intensive weight-loss lifestyle intervention, including physical activity, based on the traditional Mediterranean food pattern is a sustainable long-term approach for weight reduction among overweight/obese adults and that the achieved lifestyle changes will exert beneficial effects on cardiovascular disease incidence, according to our experience (Estruch R et al., 2012) and research by other investigators (Shai et al., 2008). The rationale for the proposed investigation is that it can provide a new, affordable, and sustainable approach to reduce excess cardiovascular morbidity and mortality among overweight/obese adults, beyond what was already observed in the PREDIMED I trial.



​​ ​​
Funding Agency: European Commission, General Programme FP7
Collaborative project title: Satiety control through food structures made by novel processing (SATIN).
Cooperation Work Programme: Food, Agriculture and Fisheries and Biotechnologies
Call Identifier: FP7-KBBE-2011-5
Proposal No: 289800 SATIN (Satiety Innovation)
SATIN Project Coordinator: Dr. Jason Halford, University of Liverpool (UK)
Principal Investigator of Group: Work package V: Dr. Mònica Bulló Bonet
Duration: 01-Jan-2012 to 31-Dec-2016
Members of the group participants as researchers: Salas-Salvadó J, Investigator of WP5
http://www.satin-satiety.eu
https://cordis.europa.eu/project/id/289800/es

The SATIN project has been devised to develop food products produced by novel food processing that control satiety through modification of food structure. To achieve this the SATIN project will:
1. Integrate advanced technologies to screen novel food structures through in vitro models to isolate and refine products according to their satiating potential. 2. Develop novel food processing technologies that combine active ingredients and change food structure to produce a range of novel satiety enhancing ingredients. 3. Produce finished foods products that pass through safety analysis, early sensory evaluation and consumer testing. 4. Demonstrate the effects of prototype products on biomarkers of satiety and on nutrient bioavailability using in vivo studies and validating new in vivo approaches. 5. Demonstrate the effects of final foods products on within-meal satiation, post-meal satiety and / or reduced appetite and biomarkers of satiety. 6. Demonstrate the enduring effects of individual food products on satiety and their potential to induce weight loss. 7. Demonstrate the long-term consumer and health benefits of adhering to a diet containing satiety enhancing products. 8. Validate health claim endpoints and commercialise technologies and products.
The SATIN consortium consists of 7 SMEs and 4 commercial partners ensuring that advanced technologies developed to process and screen novel food products are applied to the food industry and improve European economic competitiveness. The safety and efficacy of products developed will be rigorously examined by 7 leading international academic research teams ensuring consumers will have new high quality processed foods to help them achieve a balanced diet.



​​
Funding Agency: DGJR - European Commission Directorate General Joint Research Centre; European Commission - Public Health 2004
Project title: Diabetes in Europe: Prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN).
Project Coordinator: Prof. Jaakko Tuomioletho, Helsinki University (FIN) Dossier: 2004310
Principal Investigator: Bernardo Costa Pinel
Members of the group participants as researchers: Salas-Salvadó J, Bulló M.
Duration: 2005 - 2009